Seer, Inc. (SEER) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Seer, Inc. is a life sciences technology company focused on the Proteograph Product Suite, which utilizes proprietary engineered nanoparticle technology for deep proteomic analysis. The company is in the early stages of commercialization, transitioning from R&D to broader market adoption. As of the reporting date, the company is classified as a smaller reporting company and a non-accelerated filer.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $4.12 million | $4.03 million | $12.38 million | $10.17 million |
| Gross Profit | $2.11 million | $1.94 million | $6.28 million | $5.03 million |
| Gross Margin | 51.2% | 48.1% | 50.7% | 49.5% |
| Operating Loss | $(19.35) million | $(24.33) million | $(60.61) million | $(76.61) million |
| Net Loss | $(18.23) million | $(21.33) million | $(57.61) million | $(64.86) million |
| Net Loss Per Share (Basic/Diluted) | $(0.32) | $(0.35) | $(0.99) | $(1.02) |
| Cash & Investments | $251.2 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $450.0 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 22% year-over-year for the nine months ended September 30, 2025, driven by a 32% increase in product revenue and a 66% increase in service revenue. However, related party revenue decreased 60% year-over-year.
- Expense Reduction: Operating expenses decreased significantly. Research and Development (R&D) expenses fell 10% YTD, and Selling, General, and Administrative (SG&A) expenses dropped 25% YTD. These reductions were primarily due to lower stock-based compensation and reduced professional service fees.
- Improved Loss Profile: The net loss narrowed by 11% on a YTD basis compared to the prior year, reflecting the combination of revenue growth and disciplined cost management.
- Share Repurchases: The company repurchased approximately 5.23 million shares of Class A common stock for $10.14 million during the first nine months of 2025.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management expects to continue incurring significant operating losses and negative cash flows from operations for the foreseeable future. However, with $251.2 million in cash, cash equivalents, and investments, the company believes it has sufficient capital to fund operations for at least the next twelve months.
Commercial Strategy: The company is focused on the broad commercialization of the Proteograph Product Suite, including the new Proteograph ONE Assay and SP200 Automation Instrument launched in May 2025. International revenue now accounts for 48% of total revenue for the quarter, up from 29% in the prior year.
Key Risks and Contingencies:
- Profitability: There is no assurance the company will ever achieve or sustain profitability.
- Customer Concentration: While no single customer exceeded 10% of revenue in the first nine months of 2025, the company remains dependent on a small number of customers and related parties (e.g., PrognomiQ).
- Supply Chain: The company relies on a single contract manufacturer (Hamilton Company) for its automation instruments.
- Intellectual Property: The company faces ongoing patent challenges, including Inter Partes Review proceedings in the U.S. and opposition actions in Europe regarding licensed patents.
- Regulatory: Products are currently labeled for Research Use Only (RUO). Future expansion into clinical diagnostics would require FDA clearance or approval, which is costly and uncertain.
Investor Verification Checklist
- Runway Validation: Verify the $251.2 million cash position against current burn rates to confirm the 12-month liquidity assertion.
- Revenue Quality: Analyze the sustainability of the 66% increase in service revenue and the 60% decline in related party revenue.
- Stock-Based Compensation: Review the impact of the significant decrease in stock-based compensation ($12.1M YTD 2025 vs $21.8M YTD 2024) on future expense projections.
- Share Repurchase Impact: Assess the remaining $3.1 million authorization under the share repurchase program and its effect on cash reserves.
- Patent Status: Monitor the outcome of the Inter Partes Review (IPR2024-01473) and European oppositions regarding the '360 patent and other licensed IP.